The first international symposium of Prestige Biopharma IDC was a meaningful event that shared advanced biopharmaceutical technologies and platform development achievements while discussing the possibilities of collaboration and innovation.On the first day, presentations covered topics such as disease modulation, new drug development strategies, and immune-modulating virus therapies, offering insights into the future of advanced biotechnologies.On the second day, discussions focused on global biopharma collaboration and innovation cases, strategies for supporting biotech startups, and R&D cooperation achievements, with panel discussions presenting growth directions and collaboration strategies for the biopharma industry.This symposium served as an opportunity to foster networking and information exchange among experts, solidifying Prestige Biopharma IDC's vision to become a global innovation hub in the biopharma industry.

Prestige Biopharma Group has taken its first step toward becoming a global innovation hub in the biopharma industry with the opening ceremony of its R&D control tower, the Innovation Drug Center (IDC).With its cutting-edge research platform and global network, IDC is dedicated to the development of antibody therapeutics and biosimilars for the treatment of intractable diseases, embodying the vision of "Innovation for Life."The international symposium held alongside the opening ceremony provided an opportunity to share achievements in biopharmaceutical technologies and platform development, while exploring the possibilities of collaboration and innovation.Moving forward, IDC aims to lead the global biopharma industry and establish itself as a world-class biopharma cluster.We kindly ask for your continued interest and support in the journey of the Innovation Drug Center.

Prestige Biologics has been named ‘Best Biologics CMO in South Korea’ at the Biologics Contract Manufacturing Asia 2024!With expertise in single-use and scale-out biomanufacturing, we continue to deliver top-quality CDMO services.   

BIO USA 2024 has opened today in the United States.Prestige Biopharma Group is continuing with over 30 meetings on the first day.All employees are committed to doing their best to achieve successful outcomes.

Prestige Biologics, a Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, has signed a biologics manufacturing deal with Celltrion, a developer of the world's first monoclonal antibody biosimilar.The 5-year agreement will establish Prestige Biologics as a leading biologics manufacturing company in Osong, one of the biggest biomedical hubs in South Korea. This collaboration with Celltrion underscores Prestige Biologics' expertise in biopharmaceuticals, solidifying its prominent position in the rapidly evolving field of biologics manufacturing."We are pleased to announce our partnership with Celltrion,” stated Jae Young Yang, Director of the Business Development (BD) Center. “This contract holds a significant meaning as it marks the official beginning of Prestige Biologics’ CDMO business. This proven track record with Celltrion will pave the way for future contracts with global biologics clients.”Prestige Biologics is a biopharmaceutical CDEMO (Contract Development Engineering and Manufacturing Organization) that operates production facilities based in South Korea. With a manufacturing capacity of 154,000 litres, Prestige Biologics stands as one of the top 10 global CDMO companies working with animal cell culture.Celltrion is a leading biopharmaceutical company dedicated to developing innovative therapeutics that improve patients’ health and well-being. The company’s therapeutic solutions include monoclonal antibody biosimilars such as Remsima(Infliximab), Herzuma(Trastuzumab), Truxima(Rituximab), Remsima SC(Infliximab), Yuflyma(Adalimumab), and Vegzelma(Bevacizumab).

Prestige Biologics has been nominated in three categories at the Asia-Pacific Biopharma Excellence Awards (ABEA) hosted by IMAPAC in 2024.Following our recognition in 2022, we are thrilled to announce our candidacy in three categories this year.The three categories in which Prestige Biologics has been nominated for ABEA are as follows:1. Bioprocessing Excellence in Korea - Prestige Biologics2. Bioprocessing Leadership Award - Duk Hoon Hyun, CEO, Prestige Biologics3. Best Contract Development and Manufacturing Award - Prestige BiologicsIn the first category, Prestige Biologics is nominated for Bioprocessing Excellence within the Korean region, alongside other prominent biopharmaceutical manufacturing companies.The second category features Duk Hoon Hyun, CEO of Prestige Biologics, as a nominee for the Bioprocessing Leadership Award. His leadership has garnered high praise for securing financial stability through financial investments during the 2022-2023 period. Additionally, his efforts in consistently improving the CDMO production base to provide high-quality services to global customers and the commitment to quality assurance through digital transformation have been recognized.In the third category, Prestige Biologics is nominated for the Best CDMO Award, reflecting the company's standing as a valuable CDMO production facility in the Asia-Pacific region, along with the accumulated technological and experiential value.Regardless of the outcome, being nominated in three categories at the 2024 awards has been a significant source of encouragement and motivation for Prestige Biologics and its partners. We remain committed to contributing to the biopharmaceutical supply ecosystem through continuous process improvement and innovation.